BHVNHealthcare · BiotechnologyThe 16 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $20 — +27.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (78): Sales and profits are climbing, and climbing faster than before.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.5% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | $18 → $19 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $22 → $23 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $12 → $11 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Maintains | Outperform | — |
| 2 Apr 2026 | Citigroup | Maintains | Buy | — |
| 11 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 3 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 21 Jan 2026 | RBC Capital | Upgrade | Outperform | — |
| 6 Jan 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Dec 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 3 Dec 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 26 Nov 2025 | UBS | Downgrade | Neutral | — |
| 20 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 18 Nov 2025 | BTIG | Reiterates | Buy | — |
| 18 Nov 2025 | Morgan Stanley | Maintains | Overweight | — |
| 13 Nov 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHVN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Biohaven Ltd. returned −2.4% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 1% of US stocks
Cheaper than 78% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biohaven Ltd. has a market value of $2.4B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$586.8M.
Diluted earnings per share, trailing twelve months: $−4.64.
Free cash flow in the twelve months to 30 June 2026: −$511.9M.
Trailing P/E: −2.3×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Biohaven Ltd. employs 274 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biohaven's stock performed strongly this week, with the company's partner being South Korean peer SK Biopharmaceuticals. Biohaven also secured a victory in a lawsuit.
Why it matters — A BHVN watcher would care because the partnership with SK Biopharmaceuticals and the legal victory highlight positive developments supporting the company's pipeline and position.
Seeking Alpha reiterates a Buy rating on Biohaven Ltd., citing progress in its protein degrader trials and a licensing agreement with SK Biopharmaceuticals for its Kv7 platform. The company's BHVN-1300 phase 3 for Graves' disease is underway, BHV-1400's phase 3 for IgA nephropathy is planned for H2 2026, and its opakalim (BHV-7000) candidate for refractory focal epilepsy is fully enrolled in phase 2/3 with topline data expected in H2 2026.
Why it matters — BHVN watchers would care because the article highlights multiple pipeline milestones and a $350M upfront licensing deal that could shape the company's near-term clinical and financial outlook.
Biohaven entered a $795M global licensing agreement with SK Biopharmaceuticals covering its Kv7 ion channel platform, including opakalim. The deal strengthens Biohaven's cash position, reduces R&D costs, and extends its funding runway.
Why it matters — This deal addresses prior liquidity concerns while the company advances degrader pipeline assets targeting large autoimmune markets and prepares pivotal trial initiations.
Biohaven's stock rose 18% following a $795 million out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
Why it matters — This transaction provides Biohaven with substantial upfront and milestone payments while another company assumes global development and commercialization of its epilepsy program, a significant validation of that asset.
Biohaven announced two major wins this week: it signed a licensing agreement with SK Biopharmaceuticals Co. Ltd. and, alongside Yale University, secured a legal victory in a trade-secret dispute.
Why it matters — A BHVN watcher would care because the new licensing deal and the favourable legal outcome both mark significant positive developments for the company.
The 16 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Biohaven Ltd., 13 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 31 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Biohaven Ltd. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +27.5% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 31 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $42 over the next 12 months.
Biohaven Ltd. returned -2.4% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.
The most recent item we track (The Motley Fool, 28 Aug 2026): "Why Biohaven Stock Was Rocking the Market This Week". Biohaven's stock performed strongly this week, with the company's partner being South Korean peer SK Biopharmaceuticals. Biohaven also secured a victory in a lawsuit.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.
CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com
